Skip to main content

United States News All stories

Every story in this section, newest first — page 353 of 373.

Grafa
Health

Cycurion reports $80M contracted backlog and strong liquidity

Cycurion closed 2025 with a strong financial position, reporting an $80 million contracted backlog and bolstered liquidity as the company accelerates into 2026.

For the third quarter of 2025, Cycurion, which trades on the Nasdaq under the ticker CYCU, reported revenue of $3.83 million, a 13.9% year-over-year decrease. However, total assets grew to $32.31 million, an increase of 26.4%, and cash reserves rose significantly to $3.65 million, compared to just $0.04 million at the end of 2024.

The company saw net financing inflows of $10.78 million and is forecasting a Q1 2026 run-rate revenue of approximately $4.17 million, which would annualize to around $16.66 million.

Recent business wins include a multi-year telecom deployment with potential revenue exceeding $1 million, a state and local government data modernization project, and a $1.1 million county contract. Cycurion also declared a pro-rata share dividend of $0.0080 per share, payable around December 30, 2025.

Cycurion’s strategic focus on government and commercial sectors continues to drive growth as the company strengthens its foundation for expansion into 2026.

Read more: Cycurion reports $80M contracted backlog and strong liquidity
Grafa
Health

Denali’s brain-penetrant therapy shows 91% biomarker reduction in Hunter syndrome

Denali Therapeutics (NASDAQ:DNLI) announced promising Phase 1/2 results for tividenofusp alfa (DNL310) in the treatment of Hunter syndrome, with the data published in The New England Journal of Medicine supporting an FDA Priority Review. The FDA has set a Prescription Drug User Fee Act (PDUFA) date for April 5, 2026.

Read more: Denali’s brain-penetrant therapy shows 91% biomarker reduction in Hunter syndrome
Grafa
Health

XOMA Royalty and Takeda amend 2006 collaboration, adjust royalty terms

XOMA Royalty (NASDAQ:XOMA) announced the amendment of its 2006 collaboration agreement with Takeda (NYSE:TAK), marking a strategic shift in the economics of their partnership.

The deal, announced on Dec. 30, 2025, will see Takeda regain the majority of XOMA Royalty's economics related to mezagitamab, a monoclonal antibody for inflammatory diseases.

Read more: XOMA Royalty and Takeda amend 2006 collaboration, adjust royalty terms
Grafa
Health

IM Cannabis explores U.S. market entry following Trump’s rescheduling directive

IM Cannabis Corp. (NASDAQ:IMCC) announced on Tuesday that it has launched a comprehensive review of strategic options to enter the United States cannabis market.

The pivot follows a landmark executive order signed by President Donald Trump on Dec. 18, 2025, which directs the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).

Read more: IM Cannabis explores U.S. market entry following Trump’s rescheduling directive
Grafa
Health

InflaRx discloses efficacy signals in failed Phase 3 skin disease trial

InflaRx N.V. (NASDAQ:IFRX) provided an update on its Phase 3 study of vilobelimab in pyoderma gangrenosum (PG), outlining multiple data analyses after the trial was terminated earlier this year due to futility, following a recommendation from an Independent Data Monitoring Committee (IDMC).

Read more: InflaRx discloses efficacy signals in failed Phase 3 skin disease trial
Grafa
Transport and logistics

Bridger Aerospace scales up firefighting fleet with $50M aircraft purchase

Bridger Aerospace Group Holdings (NASDAQ:BAER) has finalized the acquisition of six additional aircraft, a strategic expansion that solidifies its position as the owner of the world’s largest private "Super Scooper" fleet ahead of the 2026 wildfire season.

Read more: Bridger Aerospace scales up firefighting fleet with $50M aircraft purchase